Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma | Leukemia
Bortezomib Teva 3.5 mg | Medic
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
Bortezomib 26-S 3.5mg sol iny - Solmedix
Velcade: Uses, Dosage & Side Effects, Mechanism of Action - Meds Safety
Bortezomib 3,5 mg | Laboratorio Chile | Teva
Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Bortezomib-Teva®
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
AUSTRALIAN PRODUCT INFORMATION – BORTEZOMIB-TEVA (BORTEZOMIB) POWDER FOR INJECTION 1 NAME OF THE MEDICINE 2 & 3 QUALITATIV
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink
Biomolecules | Free Full-Text | Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations | HTML
/cdn.vox-cdn.com/uploads/chorus_asset/file/6129353/bmj.png "Drug companies will earn $1.8 billion this year from cancer drugs that patients never take - Vox")
Drug companies will earn $1.8 billion this year from cancer drugs that patients never take - Vox
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis
Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis - ScienceDirect
View of Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored at 4°C and Room Temperature (23°C or 25°C) | Canadian Journal of Hospital Pharmacy
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
